BR112018070971A2 - métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia - Google Patents
métodos e kits para a diagnose e estratificação de risco de pacientes com isquemiaInfo
- Publication number
- BR112018070971A2 BR112018070971A2 BR112018070971A BR112018070971A BR112018070971A2 BR 112018070971 A2 BR112018070971 A2 BR 112018070971A2 BR 112018070971 A BR112018070971 A BR 112018070971A BR 112018070971 A BR112018070971 A BR 112018070971A BR 112018070971 A2 BR112018070971 A2 BR 112018070971A2
- Authority
- BR
- Brazil
- Prior art keywords
- ischemia
- methods
- diagnosis
- kits
- patients
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000028867 ischemia Diseases 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000013517 stratification Methods 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382167.1A EP3232200A1 (en) | 2016-04-12 | 2016-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
| PCT/EP2017/058768 WO2017178521A1 (en) | 2016-04-12 | 2017-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018070971A2 true BR112018070971A2 (pt) | 2019-01-29 |
Family
ID=56008566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018070971A BR112018070971A2 (pt) | 2016-04-12 | 2017-04-12 | métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11486884B2 (enExample) |
| EP (2) | EP3232200A1 (enExample) |
| JP (1) | JP7075894B2 (enExample) |
| KR (1) | KR102344344B1 (enExample) |
| CN (1) | CN109154620B (enExample) |
| AU (1) | AU2017251355A1 (enExample) |
| BR (1) | BR112018070971A2 (enExample) |
| CA (1) | CA3020666A1 (enExample) |
| ES (1) | ES2979390T3 (enExample) |
| IL (1) | IL262245B (enExample) |
| MA (1) | MA44658A (enExample) |
| MX (1) | MX2018012580A (enExample) |
| RU (1) | RU2750035C2 (enExample) |
| SG (1) | SG11201808820QA (enExample) |
| WO (1) | WO2017178521A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022506108A (ja) * | 2018-10-23 | 2022-01-17 | グリカルディアル ダイアグノスティクス エセ． エレ． | グリコシル化ＡｐｏＪに特異的な抗体およびその使用 |
| WO2020115095A2 (en) * | 2018-12-05 | 2020-06-11 | Glycardial Diagnostics, S.L. | Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury |
| KR102158726B1 (ko) | 2019-04-17 | 2020-09-22 | 한림대학교 산학협력단 | Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물 |
| KR102281657B1 (ko) | 2019-12-23 | 2021-07-26 | 한림대학교 산학협력단 | 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커 |
| KR102281644B1 (ko) | 2019-12-23 | 2021-07-23 | 한림대학교 산학협력단 | 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커 |
| KR102312534B1 (ko) | 2019-12-31 | 2021-10-13 | 한림대학교 산학협력단 | 뇌척수액 유래 미토콘드리아 마커를 이용한 지연성 허혈 진단 방법 |
| KR102318236B1 (ko) | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법 |
| KR102336507B1 (ko) | 2020-02-21 | 2021-12-06 | 한림대학교 산학협력단 | 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법 |
| KR102369155B1 (ko) | 2020-07-07 | 2022-02-28 | 한림대학교 산학협력단 | 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법 |
| KR102473349B1 (ko) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 kifap3 유전자 과메틸화 마커 |
| KR102473350B1 (ko) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커 |
| KR102496589B1 (ko) | 2020-09-11 | 2023-02-03 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 vhl 유전자 과메틸화 마커 |
| KR102473348B1 (ko) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커 |
| KR102477500B1 (ko) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 oprm1 유전자 과메틸화 마커 |
| KR102477501B1 (ko) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 alb 유전자 저메틸화 마커 |
| KR102477502B1 (ko) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커 |
| KR102466956B1 (ko) | 2020-11-05 | 2022-11-11 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 dapk1 바이오마커 |
| KR102470789B1 (ko) | 2020-11-05 | 2022-11-25 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 pink1 바이오마커 |
| KR102398533B1 (ko) | 2020-11-05 | 2022-05-13 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 뇌척수액 마이토파지 마커 |
| KR102398534B1 (ko) | 2020-11-05 | 2022-05-13 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 bnip3l 바이오마커 |
| CN113462744B (zh) * | 2021-05-24 | 2023-06-23 | 中国药科大学 | N-乙酰葡萄糖胺作为标志物在制备诊断缺血性脑中风试剂中的应用 |
| KR102865129B1 (ko) | 2021-08-06 | 2025-09-26 | 에이치앤비지노믹스 주식회사 | 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140045A (en) | 1995-03-10 | 2000-10-31 | Meso Scale Technologies | Multi-array, multi-specific electrochemiluminescence testing |
| CA2301634A1 (en) * | 1997-07-15 | 1999-01-28 | Pradeep Ghosh | Determining alcohol intake using sialic acid/apo j |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| EP1746902A4 (en) * | 2004-05-05 | 2007-06-13 | Univ Northeastern | MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF |
| JP6028960B2 (ja) * | 2009-07-14 | 2016-11-24 | 国立研究開発法人産業技術総合研究所 | 肝疾患病態指標糖鎖マーカー |
| ES2364169B1 (es) | 2010-02-09 | 2012-07-10 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) | Uso de las isoformas de apo j como biomarcadores de lesión tisular. |
| EP2400304A1 (en) * | 2010-06-22 | 2011-12-28 | Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) | Method for the characterization of intermolecular interactions |
| JP2012107932A (ja) | 2010-11-16 | 2012-06-07 | Mitsubishi Chemicals Corp | Ｃｌｕｓｔｅｒｉｎ蛋白質による脳梗塞の検査方法 |
| DK3289363T3 (da) | 2015-04-30 | 2022-02-28 | Idexx Lab Inc | Specifik påvisning af clusterin isoformer |
| CN107957498A (zh) * | 2016-10-18 | 2018-04-24 | 厦门德馨尚品医疗科技有限公司 | 一种含有载脂蛋白j的试剂盒及其在临床诊断中的应用 |
-
2016
- 2016-04-12 EP EP16382167.1A patent/EP3232200A1/en not_active Withdrawn
-
2017
- 2017-04-12 MX MX2018012580A patent/MX2018012580A/es unknown
- 2017-04-12 US US16/092,703 patent/US11486884B2/en active Active
- 2017-04-12 JP JP2018554391A patent/JP7075894B2/ja active Active
- 2017-04-12 AU AU2017251355A patent/AU2017251355A1/en not_active Abandoned
- 2017-04-12 CA CA3020666A patent/CA3020666A1/en active Pending
- 2017-04-12 SG SG11201808820QA patent/SG11201808820QA/en unknown
- 2017-04-12 BR BR112018070971A patent/BR112018070971A2/pt not_active Application Discontinuation
- 2017-04-12 ES ES17717159T patent/ES2979390T3/es active Active
- 2017-04-12 EP EP17717159.2A patent/EP3443353B1/en active Active
- 2017-04-12 KR KR1020187032609A patent/KR102344344B1/ko not_active Expired - Fee Related
- 2017-04-12 WO PCT/EP2017/058768 patent/WO2017178521A1/en not_active Ceased
- 2017-04-12 MA MA044658A patent/MA44658A/fr unknown
- 2017-04-12 CN CN201780029342.8A patent/CN109154620B/zh not_active Expired - Fee Related
- 2017-04-12 RU RU2018139780A patent/RU2750035C2/ru active
-
2018
- 2018-10-09 IL IL262245A patent/IL262245B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201808820QA (en) | 2018-11-29 |
| RU2018139780A (ru) | 2020-05-12 |
| IL262245A (en) | 2018-11-29 |
| KR102344344B1 (ko) | 2021-12-28 |
| EP3443353A1 (en) | 2019-02-20 |
| JP7075894B2 (ja) | 2022-05-26 |
| CN109154620A (zh) | 2019-01-04 |
| EP3232200A1 (en) | 2017-10-18 |
| RU2750035C2 (ru) | 2021-06-21 |
| US20190128900A1 (en) | 2019-05-02 |
| KR20190008216A (ko) | 2019-01-23 |
| ES2979390T3 (es) | 2024-09-25 |
| CN109154620B (zh) | 2022-03-08 |
| RU2018139780A3 (enExample) | 2020-07-24 |
| EP3443353B1 (en) | 2024-03-13 |
| JP2019516966A (ja) | 2019-06-20 |
| US11486884B2 (en) | 2022-11-01 |
| AU2017251355A1 (en) | 2018-11-08 |
| MX2018012580A (es) | 2019-02-25 |
| MA44658A (fr) | 2019-02-20 |
| CA3020666A1 (en) | 2017-10-19 |
| IL262245B (en) | 2021-03-25 |
| WO2017178521A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018070971A2 (pt) | métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia | |
| BR112017005730A2 (pt) | predição de evento de risco cardiovascular e usos da mesma | |
| WO2014201516A3 (en) | Biomarker identification | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BR112014029233A8 (pt) | método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio | |
| BR112013006764A2 (pt) | método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente | |
| MX2017008904A (es) | Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica. | |
| BR112017014419A2 (pt) | diagnose e tratamento de diabetes incipiente | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| BR112018011224A2 (pt) | processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs) | |
| BR112013019563A2 (pt) | métodos para prognóstico de ferida, para tratamento de ferida, para prognosticar se um paciente pode ser responsivo ao tratamento de uma ferida que exsuda um fluido de ferida, e para tratar uma ferida que exsuda um fluido de ferida, dispositivo para medir simultaneamente ou sequencialmente os níveis de hne e de pelo menos uma mmp em uma amostra de fluido de ferida, aparelho para diagnóstico, e, estojo. | |
| BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
| BR112018008799A2 (pt) | método de prognóstico | |
| BR112019005167A2 (pt) | método e kit para analisar uma amostra | |
| BR112019005172A2 (pt) | método e kit para analisar uma amostra | |
| BR112016023170A2 (pt) | biomarcadores para avaliação de hiv | |
| BR112018073214A2 (pt) | métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador | |
| BR112015029852A2 (pt) | método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9 | |
| BR112016029562A2 (pt) | métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica | |
| WO2015006657A8 (en) | Method for the diagnosis and prognosis of cancer | |
| BR112014010529A2 (pt) | agente, métodos para tratar hipertensão pulmonar, e, método de diagnóstico ou de prognóstico para a determinação se um paciente teve ou tem uma predisposição à hipertensão pulmonar | |
| BR112018009879A2 (pt) | biomarcador da doença renal policística e seus usos | |
| BR112017027304A2 (pt) | método para o diagnóstico de doença de farber | |
| BR112017002856A2 (pt) | dispositivo, e, método |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |